Evidence map›Paper›PMID 30057760›Full record

ArticleBritish journal of pain2018

The use of fentanyl in pain management in head and neck cancer patients: a narrative review.

Raffaele Giusti, Paolo Bossi, Marco Mazzotta, Marco Filetti, Daniela Iacono, Paolo Marchetti

Open access · greenAbstract read
In one paragraph

Article in British journal of pain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Is pain part of a systemic syndrome in head and neck cancer?Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Raffaele GiustiMedical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy.
Paolo BossiMedical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Marco MazzottaMedical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy.
Marco FilettiMedical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy.
Daniela IaconoPulmonary Oncology Unit, San Camillo Forlanini Hospital, Rome, Italy.
Paolo MarchettiMedical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy.
CTO Andrea Alesini · ITCarlo Forlanini Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHead and neck (H&N) cancers account for about 5% of all malignant tumours. Pain is one of the most feared consequences of H&N neoplasms and is experienced by up to 80% of patients and worsens their quality of life inhibiting speaking, eating, drinking or swallowing. Nevertheless, pain is still often underestimated and undertreated.

objectivesThe role of opioids in cancer pain has been well established but evidences about the role and the relative effectiveness of opioids such as fentanyl in the context of H&N cancer pain remains unclear.

methodsA literature review based on the guidance of the Centre for Reviews and Dissemination was conducted. An iterative approach was used starting with an electronic search in the MEDLINE database. The search terms

resultsA total of 18 publications were found by the first performed search on PubMed. Other publications concordant with our aim were found by cross-reference. Considering inclusion and exclusion criteria for our review, eight papers resulted eligible for analysis.

conclusionFentanyl transdermal therapeutic system (TTS) seems to be an important option, thanks to the way of administration, the good safety and tolerability profiles to control baseline pain. For breakthrough cancer pain (BTcP), several formulations of transmucosal fentanyl are available. All the formulations seem to be active and safety but we lack head-to-head studies of fentanyl versus other strong opioids, as well as with different formulation of fentanyl, particularly for BTcP where H&N cancer population is very poorly represented.

Indexed as

breakthrough painfentanylHead and neck canceropioidspain

Identifiers

PMID30057760
PMCPMC6058455
OpenAlexW2763099317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.